Novo Nordisk A/S is a global pharmaceutical company specializing in research, development, and manufacturing of treatments for serious chronic diseases. Founded through the 1989 merger of Danish insulin pioneers Nordisk Insulaboratorium and Novo Terapeutisk Laboratorium, it traces its roots to 1923 when commercial insulin production began in Denmark following its discovery. Headquartered in Bagsværd, Denmark, the company employs over 77,000 people worldwide and markets products in more than 168 countries. It holds a leading position in diabetes care, commanding roughly one-third of the global branded market with insulins like Tresiba and Levemir, and GLP-1 therapies such as Ozempic and Rybelsus. Novo Nordisk A/S also excels in obesity treatments with Wegovy and Saxenda, alongside therapies for rare diseases including hemophilia (NovoSeven, Esperoct), growth disorders (Norditropin), and hormone replacement. Its biopharmaceutical innovations, including smart insulin pens and delivery systems, underscore its commitment to accessibility and patient-centered solutions, significantly influencing healthcare sectors focused on metabolic, cardiovascular, and endocrine conditions.